Table 1.
Baseline and tumor characteristics of patients < 75 years treated with neoadjuvant chemotherapy and patients ≥ 75 years treated with or without neoadjuvant chemotherapy
| Patients characteristics | 1 | 2 | 3 | 1 versus 2 | 2 versus 3 |
|---|---|---|---|---|---|
| Neoadjuvant chemotherapy age < 75 (N = 1249) | Neoadjuvant chemotherapy age ≥ 75 (N = 275) | No neoadjuvant chemotherapy age ≥ 75 (N = 471) | P-value | P-value | |
| Age, median (IQR), years | 64 (57–70) | 77 (76–78) | 80 (78–83) | < 0.001 | < 0.001 |
| Sex, male no./total no. (%) | 824 (66.0) | 172 (62.5) | 285 (60.5) | 0.280 | 0.622 |
| WHO performance status, no./total no. (%) | 0.348 | < 0.001 | |||
| 0 | 540 (43.2) | 103 (37.5) | 92 (19.5) | ||
| 1 | 408 (32.7) | 96 (34.9) | 126 (26.8) | ||
| ≥ 2 | 49 (3.9) | 13 (4.7) | 68 (14.4) | ||
| Unknown | 252 (20.2) | 63 (22.9) | 185 (39.3) | ||
| ASA classification, no./total no. (%) | < 0.001 | < 0.001 | |||
| 1 | 77 (6.2) | 7 (2.5) | 6 (1.3) | ||
| 2 | 615 (49.2) | 103 (37.5) | 195 (41.1) | ||
| ≥ 3 | 266 (21.3) | 78 (28.4) | 230 (48.8) | ||
| Unknown | 291 (23.3) | 87 (31.6) | 40 (8.5) | ||
| Number of comorbidity categories, no./total no. (%) | < 0.001 | 0.224 | |||
| 0 | 633 (50.7) | 112 (40.7) | 162 (34.4) | ||
| 1 | 360 (28.8) | 90 (32.7) | 159 (33.8) | ||
| ≥ 2 | 149 (11.9) | 55 (20.0) | 121 (25.7) | ||
| Unknown | 107 (8.6) | 18 (6.5) | 29 (6.2) | ||
| Year of diagnosis no./total no. (%) | 0.414 | 0.062 | |||
| 2015 | 255 (20.4) | 52 (18.9) | 105 (22.3) | ||
| 2016 | 267 (21.4) | 48 (17.5) | 106 (22.5) | ||
| 2017 | 220 (17.6) | 48 (17.5) | 92 (19.5) | ||
| 2018 | 266 (21.3) | 70 (25.5) | 85 (18.0) | ||
| 2019 | 241 (19.3) | 57 (20.7) | 83 (17.6) | ||
| Tumor location, no./total no. (%) | 0.028 | < 0.001 | |||
| Proximal | 653 (52.3) | 126 (45.8) | 164 (34.8) | ||
| Distal | 420 (33.6) | 99 (36.0) | 244 (51.8) | ||
| Whole stomach | 156 (12.5) | 39 (14.2) | 26 (5.5) | ||
| Unknown | 20 (1.6) | 11 (4.0) | 37 (7.9) | ||
| cT-stage, no./total no. (%) | 0.320 | < 0.001 | |||
| T1–T2 | 420 ( 33.6) | 105 (38.2) | 207 (43.9) | ||
| T3–T4a | 657 (52.6) | 132 (48.0) | 137 (29.1) | ||
| Tx | 172 (13.8) | 38 (13.8) | 127 (27.0) | ||
| cN-stage, no./total no. (%) | 0.400 | < 0.001 | |||
| N0 | 642 (51.4) | 148 (53.8) | 332 (70.5) | ||
| N1 | 338 (27.1) | 80 (29.1) | 94 (20.0) | ||
| ≥ N2 | 215 (17.2) | 39 (14.2) | 30 (6.4) | ||
| Nx | 54 (4.3) | 8 (2.9) | 15 (3.2) | ||
| Tumor differentiation, no./total no. (%) | 0.044 | < 0.001 | |||
| Well-moderate | 343 (27.5) | 95 (34.5) | 174 (36.9) | ||
| Poorly | 644 (51.6) | 122 (44.4) | 246 (52.2) | ||
| Unknown | 262 (21.0) | 58 (21.1) | 51 (10.8) |
IQR interquartile range, WHO World Health Organization, ASA American Society of Anesthesiologists Classification